Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK0901 in Children With ADHD
CTR20240367Phase 3Completed
- Sponsor
- Commave Therapeutics
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of serdexmethylphenidate + dexmethylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Commave Therapeutics. Started Feb 2024; status: completed.
02
Drugs
serdexmethylphenidate + dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20240367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240367.